“Katja and team did an excellent job communicating our key validation milestone, demonstrating that lab grown universal red blood cells have a half-life matching donated blood, as well as our financing. I was impressed by their proactivity and the targeted media coverage achieved.”

Alistair Irvine
CEO of Scarlet Therapeutics 

Objectives

  • Highlight the value of the company’s innovative lab-grown universal red blood cell-based (RBCs) technology across application areas including treatment, transfusion, and enhancement
  • Highlight successful close of a £3.2m seed financing round to take the company’s manufactured RBCs into the clinic. Loaded with therapeutic proteins, they will be used to treat rare metabolic diseases

Strategy

  • Developed messaging around key asset characteristics including that the in vivo survival of the company’s lab-grown universal RBCs is equivalent to donated blood
  • Drafted press release and accompanying media Q&A and rehearsed responses
  • Engaged with media under embargo, including an in-person interview at BioTrinity, to tell the story and secure coverage

Results

  • Secured significant trade-media coverage, including in key trade titles such as BioWorld, European Biotechnology Magazine, Labiotech, and Longevity Technology, and MedNous